Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer
Published: Nov 02, 2007
HAYWARD, Calif., Nov. 1 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, today announced the appointment of Dawn McGuire, M.D. as its Chief Medical Officer. As a board certified neurologist with more than a decade of executive leadership in drug development, including roles as CEO, Chief Scientific Officer and Chief Medical Officer, Dr. McGuire brings substantial expertise in therapeutic product development for Acologix' product pipeline.
Prior to joining Acologix, Dr. McGuire was the Chief Medical Officer of Pepgen Corporation, a privately held company based in Alameda, CA developing products for autoimmune and viral diseases. Dr. McGuire was also formerly Chief Medical Officer of Avigen, a biotechnology company focused on gene therapy in neurological disorders. At Elan Pharmaceuticals, she was Vice President of Clinical Research, where she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of multiple sclerosis (MS). From 1999 to 2002, Dr. McGuire served as Chief Executive Officer of Eunoe, Inc., a biotechnology company developing a novel device-based treatment for Alzheimer's disease.
Dr. McGuire has led programs resulting in approval from various divisions of the FDA, including Cardiorenal, Analgesia and Neuropharmacology, and was responsible for development programs in neuropathic pain, MS, Parkinson's disease, Alzheimer's disease, ALS and psoriasis, among other indications.
Dr. McGuire has published more than 40 scientific articles, book chapters and invited interviews, and has received numerous awards, including in 2005 the People to People Award for a Virtual Clinic for helping physicians treat AIDS in Ethiopia. Dr. McGuire also holds several academic and service positions, including neurological academy committee memberships, peer review committee membership in the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH), and serves on the Advisory Council of the Gill Heart Institute.
Dr. McGuire received her B.A. with high honors from Princeton University and her M.D. from Columbia University, College of Physicians & Surgeons, where she was elected to Alpha Omega Alpha medical honor society. She was trained in Neurology at the University of California, San Francisco, followed by an NIH-funded postdoctoral fellowship in clinical trial design and experimental therapeutics.
About Acologix, Inc.
Acologix, Inc. a privately held biopharmaceutical company, is developing and commercializing innovative biopharmaceuticals targeting osteo-renal diseases, including chronic kidney disease, renal osteodystrophy, bone repair and regeneration, periodontal disease, general dentistry and oral care. Acologix is partnered with Toray Industries, Inc. of Japan on the development and commercialization of AC-820 (TRK-820) for the treatment of uremic pruritus in dialysis patients. Acologix is preparing for a Phase III study with this compound for uremic pruritus in the United States for 2008. AC-100 (Dentonin(R)), a novel small peptide with dental, periodontal and orthopedic applications, has been studied in two Phase II clinical studies; one in dental restoration procedures and another for the repair of periodontal defects. Further studies to support development in orthopedic indications are ongoing. Acologix is also developing AC-200 (Phosphatonin) to treat hyperphosphatemia and subsequent clinical problems associated with chronic kidney disease. For more information, go to http://www.acologix.com.
This press release contains "forward-looking" statements. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include statements regarding product development and cannot be guaranteed. Acologix undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Acologix' business.
CONTACT: Yoshi Kumagai, President and CEO of Acologix, Inc.,
+1-510-512-7200, Fax, +1-510-786-1116, firstname.lastname@example.org
Web site: http://www.acologix.com/